TriSalus Life Sciences Inc. (TLSI)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $149.93M
Last updated: Nov 17, 2026 at 11:05 AM ET
TriSalus Life Sciences Inc. (TLSI) Stock Forecast
Analysts expect TriSalus Life Sciences (TLSI) to earn -$0.44 per share in the fiscal year ending Dec 31, 2026, on revenue of $46.76M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.35.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 20.0% |
| Buy | 4 | 80.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 28.6%.
- Fiscal year ending Dec 31, 2026
- -$0.44
- EPS consensus, revenue $46.76M
- Fiscal year ending Dec 31, 2027
- -$0.35
- EPS consensus, revenue $60.11M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.44 | -$0.45 to -$0.42 | 3 | $46.76M | $46.00M to $47.30M | 3 |
| Dec 31, 2027 | -$0.35 | -$0.55 to $0.02 | 4 | $60.11M | $52.70M to $72.16M | 4 |
Quarterly Estimates
The EPS consensus falls from -$0.06 for the quarter ending Dec 31, 2026 to -$0.11 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.06 | -$0.11 to -$0.04 | 7 | $13.81M | $12.64M to $14.80M | 7 |
| Mar 31, 2027 | -$0.11 | -$0.15 to -$0.09 | 3 | $14.49M | $10.10M to $17.04M | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.33.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.44 | -$0.33 | -$0.33 | -$0.33 | -$0.33 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.35 | -$0.26 | -$0.26 | -$0.26 | -$0.26 | N/A |
| Quarter ending Mar 31, 2027 | -$0.11 | -$0.10 | -$0.10 | -$0.11 | -$0.11 | N/A |
Frequently Asked Questions About TLSI
What is the TLSI stock forecast?
Consensus analyst estimates put TriSalus Life Sciences's EPS at -$0.44 for the fiscal year ending Dec 31, 2026, on revenue of $46.76M. The consensus rating from 5 analysts is Buy.
How do analysts rate TLSI stock?
Of 5 analysts covering TriSalus Life Sciences, 1 rates it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TLSI next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.44, with estimates from -$0.45 to -$0.42 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.35, with estimates from -$0.55 to $0.02 from 4 analysts.
What revenue do analysts expect from TriSalus Life Sciences next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $46.76M, with estimates from $46.00M to $47.30M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $60.11M, with estimates from $52.70M to $72.16M.
How many analysts cover TLSI?
5 analysts rate TriSalus Life Sciences stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TLSI pages: Overview, Earnings, Forecast, Financials, Competitors